Drug Information

Drug General Information
Drug ID
D03AKH
Former ID
DNCL001755
Drug Name
CER-001
Indication Acute coronary syndrome [ICD9: 444; ICD10:I74] Phase 2 [523582]
Company
Cerenis Therapeutics
Target and Pathway
Target(s) Apolipoprotein A-I Target Info Modulator [550544]
KEGG Pathway PPAR signaling pathway
Fat digestion and absorption
Vitamin digestion and absorption
African trypanosomiasis
NetPath Pathway TGF_beta_Receptor Signaling Pathway
TNFalpha Signaling Pathway
Pathway Interaction Database FOXA2 and FOXA3 transcription factor networks
Reactome Platelet degranulation
ABC transporters in lipid homeostasis
Chylomicron-mediated lipid transport
HDL-mediated lipid transport
PPARA activates gene expression
Scavenging of heme from plasma
Scavenging by Class B Receptors
Scavenging by Class A Receptors
Retinoid metabolism and transport
Amyloid formation
WikiPathways Statin Pathway
Nuclear Receptors Meta-Pathway
PPAR Alpha Pathway
Human Complement System
Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
Binding and Uptake of Ligands by Scavenger Receptors
Visual phototransduction
Lipid digestion, mobilization, and transport
ABC-family proteins mediated transport
Folate Metabolism
Vitamin B12 Metabolism
Selenium Micronutrient Network
References
Ref 523582ClinicalTrials.gov (NCT01412034) Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects. U.S. National Institutes of Health.
Ref 550544Clinical pipeline report, company report or official report of Cerenis.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.